
Why getting rid of belly fat is key to a longer, healthier life
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Hiding deep inside the body, a dangerous type of fat wraps itself around vital organs such as the kidneys, liver and heart — triggering inflammation that can lead to insulin resistance and chronic diseases which cut life short.
Called visceral fat, it can make bellies expand — but not for everyone. Even people who are thin can carry too much visceral fat around their organs, a phenomenon known as 'skinny fat.'
'Visceral fat is a marker for everything — insulin resistance, elevated cardiovascular risk, fatty liver and type 2 diabetes — all very bad outcomes that limit a long and healthy life,' said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver.
Excessive deep belly fat is even linked to long-term cognitive health, said preventive neurologist Dr. Kellyann Niotis, who researches Alzheimer's disease and Parkinson's disease risk reduction at the Institute for Neurodegenerative Diseases in Boca Raton, Florida.
'Visceral fat is metabolically unhealthy and secretes a lot of inflammatory chemicals that can cause brain atrophy and impact cognition,' Niotis told CNN in a prior interview.
As the size of a person's belly grows, studies show the memory center of the brain shrinks and hallmark signs of Alzheimer's disease can appear — namely beta-amyloid plaques and tau tangles. This accelerated march toward dementia can begin as early as the 40s and 50s, well before any cognitive decline is apparent, according to researchers.
If visceral fat is about 10% of your body's total fat mass, that's normal and healthy, according to the Cleveland Clinic. So how do you know if that tummy starting to obscure your view of your feet is out of control? One way to tell is to measure your waistline.
Non-pregnant women with a waist size greater than 35 inches (88.9 centimeters) and men with a waist greater than 40 inches (101.6 centimeters) are at higher risk from visceral fat, according to the US Centers for Disease Control and Prevention.
You can measure your waistline yourself: Without sucking in your tummy, wrap a tape measure over your waist at the top of your hip bone (typically across the belly button). Exhale normally and measure, making sure that the tape is parallel to the floor and snug, but not tight, across the skin. (No cheating by sucking in your stomach — this is your health at risk.)
Another key sign is lean muscle mass. If you have more body fat than muscle mass, you're more likely to have visceral fat throughout the body, even the muscles, Freeman said.
You can measure lean muscle mass with a yearly DEXA scan, a large noninvasive X-ray machine that measures bone density, internal visceral fat and muscle mass. There are also over-the-counter biometric scales that track percentages of body and visceral fat and lean muscle mass.
Then there is common sense, Freeman said. Poor exercise and eating habits are a red flag for belly fat, now and in the future.
'Human beings were designed to be fit and strong and active,' he said. 'Eating unprocessed foods and not doing cardio and strength training are good signs that if you don't have excess now, you may soon — even if you don't look 'fat.''
Want to make a change? Visceral fat is reversible with lifestyle changes, Freeman said.
'The real holy grail, the elixir of youth, the key to staying young and aging gracefully is to remain strong and fit,' he said.
Always check with your doctor before beginning any new exercise program. Then start with cardio to get the heart pumping, Freeman said. A good method is to briskly walk for at least 30 minutes a day —'but when I say briskly, I mean fast enough to lose your breath and not be able to hold a conversation. Keep that up for a half hour at a minimum.'
The critical next step is to add resistance, otherwise known as strength training, he added.
'When I tell people to go walking or biking or swimming or jogging, I usually recommend that they do resistance concurrently,' Freeman said. 'Carry some weights with them, or put on a weighted backpack, put resistance on the bike or bike uphill, and put fins on their hands when they swim so that there's resistance in the water. Do whatever they need to try to combine the cardio with strength training.'
Some of the most effective resistance exercises for building lean muscle and losing fat require multiple joints in the body to work together, according to the nonprofit American Council on Exercise.
Dead lifts, lunges, planks, presses, pull-ups and push-ups require many muscles that elevate oxygen use and the release of hormones such as adrenaline that increase blood flow to muscles and boost overall heart rate — both key goals.
As you build lean muscle mass, try to add weight, increase sets and repetition, and reduce the breaks you take between exercises. If you're unsure how to do that without injuring yourself, seek out the advice of a physical trainer, the council suggests.
'If you're doing all the right things and you're not building muscle mass, talk to your doctor to rule out issues such as low testosterone that may be hindering your progress,' Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases, told CNN previously.
Plant-based diets are excellent ways to improve nutrition and lose belly fat, experts say.
'Get rid of the standard American diet, filled with all the processed foods and added fats, sugars and the like and switch to a predominantly whole foods diet,' Freeman said.
The Mediterranean diet — which is more of a lifestyle than a diet — has won top honors since 2019 for its focus on eating fruits, vegetables, grains, olive oil, nuts and seeds, while emphasizing the importance of meals with family and friends and daily exercise. The diet also slashes consumption of sweets and recommends small amounts of dairy and meat, especially red meat. Fish, however, is a staple, especially fatty fish such as sardines.
Older people who followed a lower-calorie Mediterranean diet and minimally exercised up to six days a week gained muscle and lost a significant amount of body fat by the end of a year and kept much of it off for three years, according to an October 2023 study.
A May 2024 study found the Mediterranean dietary pattern cut the risk of death for women by about 25% for more than 25 years, with reductions in both cancer and cardiovascular mortality.
Changing when you eat may also help. Try a pattern of eating called intermittent fasting or time-restricted eating, Freeman said. However, he added, it doesn't work for everyone.
'People who are struggling with weight loss have to get their bodies out of its routine, and that's very hard to do,' Freeman said. 'Some people, not everyone, respond by some degree to time-restricted eating.
'You eat breakfast at 11 o'clock, you eat dinner by five o'clock — so six hours a day you're eating, and 18 hours a day you're not. Combine that with strength and cardio training and change the type of fuel to whole foods. You put all those together, and magic things start to happen.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
32 minutes ago
- Fast Company
A vision for America's agricultural future
As I reflect on my personal health journey, it's hard not to draw a straight line from the food I ate growing up to where I am today. Food has always been central to my wellbeing. But it wasn't until I became an adult, and sick with a disease that went undiagnosed for many months, that I fully grasped the power of food to either nourish or harm. During that extremely difficult period in my life, trapped in a cycle of inconclusive tests and debilitating symptoms, I came to understand food as medicine and realized that the way our food is grown impacts not just our bodies, but also the ecosystems that sustain us. As the CEO of Rodale Institute, I believe now more than ever that soil health is human health. The land is a living, breathing organism that must be fed and cared for, just like us. When we feed the land, it feeds us. Although Rodale Institute is 78 years old and the birthplace of the modern organic movement, we maintain a start-up mentality: ambitious, forward-thinking, and focused on accelerating regenerative organic agriculture across the country. We've set a bold goal to transition one million acres of farmland to regenerative organic by 2035. Why? Because how we grow food is deeply connected to rising rates of chronic illnesses like cancer, heart disease, and diabetes. It's time to make a change. Damage the soil, damage ourselves The current state of industrial agriculture in America is alarming. This system prioritizes high yields, chemical inputs, and monocropping at the expense of human and environmental health. Modern farming depends on synthetic pesticides, herbicides, and fertilizers, many of which have been linked to serious health concerns. Studies show people exposed to these chemicals, whether through agricultural work or food consumption, face higher risks of cancer, neurological disorders, and other illnesses. This is not a theoretical concern, it's a public health crisis. Exposure to synthetic pesticides has been linked to increased rates of leukemia, non-Hodgkin's lymphoma, and prostate cancer. These chemicals may boost short-term yields, but they degrade our soil, kill beneficial microorganisms, and upset the natural balance of ecosystems. When we damage the soil, we damage our food and ourselves. Many of these chemicals also seep into waterways, polluting communities far beyond the farm. A better way forward But there is a better way forward: regenerative organic agriculture. This holistic approach prioritizes soil health, biodiversity, and ecosystem restoration. Unlike conventional farming, regenerative organic methods avoid synthetic chemicals and instead build the natural fertility and resilience of the land. It starts with soil, rebuilding soil health through techniques like crop rotation, cover cropping, and composting. These methods increase organic matter in the soil, which helps it store carbon, retain water, and support microbial life. Healthy soil produces nutrient-dense crops, which nourish the animals and people who consume them. The benefits go beyond soil. Regenerative organic farms foster biodiversity, protect pollinators, and restore natural habitats. This isn't just about growing food, it's about restoring balance to our environment and improving public health. There's a direct link between food and health. When we eat food grown with synthetic chemicals, we ingest substances that can contribute to chronic disease. But when we eat food grown in healthy, organic soil, we're fueling our bodies with the vitamins, minerals, and antioxidants they need to thrive. In this way, food becomes medicine. I've seen this firsthand. Since changing my diet to organic foods, my energy, health, and well-being have dramatically improved. That mysterious illness? It was resolved with dietary and lifestyle changes. I farmed my body back to health. And I'm not alone. Millions of Americans suffer from chronic diseases that may be linked to our food system. The evidence is clear. Our farming practices must change if we want to improve soil health and human health. Yet there's a major hurdle: Less than 1 % of U.S. farmland is USDA-certified organic, even though consumer demand for organic food is growing rapidly. Transitioning to regenerative organic farming requires commitment, training, and investment, but it's an effort we can't afford to delay. The benefits are clear, regenerative organic farming restores our soil, improves health outcomes, and protects our environment for future generations. But we need more than a few dedicated farmers to make this vision a reality. We need widespread adoption, public investment, and strong policy support. Farmers, policymakers, and consumers must come together to build a food system that prioritizes health, sustainability, and resilience. The current food system is broken, but we can fix it. By supporting regenerative organic agriculture, we ensure that our food nourishes our bodies and sustains the land. At Rodale Institute, the farm continues to teach us about reciprocity, nourishment, and connection. We are all stewards of the land and the food that we eat from it. It's time for America to make the transition to a healthier, more regenerative food system—for our health and our future.


Washington Post
38 minutes ago
- Washington Post
Manaea's return to injury-depleted Mets rotation delayed by elbow issue
NEW YORK — Mets pitcher Sean Manaea complained of elbow discomfort following his most recent minor league rehab outing, and his return to New York's injury-depleted rotation will be delayed. Manaea had an MRI on Monday that showed loose bodies in his left elbow. He received a cortisone shot and was shut down from throwing for two to three days.


Medscape
an hour ago
- Medscape
Combination Treatment Reduces Weight While Keeping Muscle
CHICAGO — Combined use of semaglutide with an investigational monoclonal antibody called bimagrumab produced significant fat mass loss while preserving lean mass, results from the phase 2b BELIEVE study found. Loss of muscle mass is an emerging concern with increasing use of GLP-1 agonists for weight loss as lean body mass is estimated to account for up to 15%-40% of total weight loss from GLP-1 drugs. One potential solution is bimagrumab, which blocks the activin pathways that inhibit growth in skeletal muscle and increases lipid storage in adipose tissue, leading to both increased muscle mass and decreased fat mass. 'We're presenting an entirely new mechanism for managing obesity. We've heard a lot about GLP-1s and their combinations. This is going to be a unique one with bimagrumab, a drug that has completely different mechanism of action,' study investigator Steven B. Heymsfield, MD, professor and director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, told Medscape Medical News . Results from the study comparing bimagrumab and semaglutide alone and in combination for treating obesity were presented on June 23, 2025, here at the American Diabetes Association 85th Scientific Sessions. Bimagrumab's effects are complementary to those of GLP-1 drugs and other appetite suppressants, explained co-investigator Louis J. Aronne, MD, professor of metabolic research and director of the Comprehensive Weight Control Center at Weill-Cornell Medical College, New York, at a press briefing. As such, he added, the drug's potential uses include being an adjunct to GLP-1 agonists for obesity induction therapy as an alternative to incretins for people who can't tolerate them or who don't respond adequately, and as a potential preferred maintenance therap. Fat Mass vs Muscle Mass The BELIEVE study was a randomized, double-blind, placebo-controlled, multicenter study in 507 adults with obesity or overweight. Participants were randomized into a total of nine groups: placebo; bimagrumab alone at doses of 10 mg/kg and 30 mg/kg; semaglutide 1.0 mg or 2.4 mg plus placebo; and one of four groups of combined bimagrumab and semaglutide — bimagrumab 10 mg/kg plus semaglutide 1 mg; bimagrumab 30 mg/kg plus semaglutide 1 mg; bimagrumab 10 mg/kg plus semaglutide 2.4 mg; or bimagrumab 30 mg/kg plus semaglutide 2.4 mg. Bimagrumab was given intravenously at weeks 4, 16, 28, and 40; subcutaneous semaglutide was given weekly. The primary treatment period was 48 weeks, followed by an open-label extension to 72 weeks with both the placebo and bimagrumab 10 mg/kg groups switching to bimagrumab 30 mg/kg. Body composition was assessed with DEXA. At week 72, body weight was reduced by 22.1% from baseline in the combined bimagrumab 30 mg/kg plus semaglutide 2.4 mg group (highest of both doses), compared with reductions of 15.7% with semaglutide 2.4 mg alone and 10.8% with bimagrumab 30 mg/kg alone. Loss of fat mass was 45.7% with the high-dose combination vs 27.8% with semaglutide 2.4 mg and 28.5% with bimagrumab 30 mg/kg alone. Lean mass loss was 2.9% with the high-dose combination, compared with a loss of 7.4% with semaglutide 2.4 mg and a gain of 2.5% with bimagrumab 30 mg/kg alone. The percentage of weight loss that was due to fat mass at week 48 was 92.9% for the high-dose combination, 71.5% for semaglutide alone, and 100% for bimagrumab alone. The proportions of participants achieving weight loss of 20% or more were 69.8% with the combination versus 25.0% with semaglutide, and 10.9% with bimagrumab. And, the proportions achieving 30% or greater fat mass reduction were 94.0%, 36.4%, and 50.0%, respectively, Heymsfield reported. Visceral adipose tissue decreased more with bimagrumab alone or in combination compared with semaglutide alone, with parallel changes from baseline in waist circumference. High-sensitivity C-reactive protein, a key inflammatory biomarker, decreased by 83% in the high-dose combination group by week 48, Aronne said. Adiponectin also increased more with bimagrumab alone or in combination compared with semaglutide alone. Both total and LDL cholesterol rose in the bimagrumab groups and then returned to baseline in the combination groups containing semaglutide 2.4 mg by week 72. Baseline LDL was 114.3 mg/dL, rising by about 15%-30% in the bimagrumab groups by 12-24 weeks. The combination groups returned to baseline by 72 weeks, whereas the bimagrumab-only group dropped, but not back to baseline. When asked about that, Aronne said 'We believe that the route of administration might be a reason for that observation. I think we need more research to figure this out.' Increased LDL Cholesterol: Is It a Concern? Asked to comment, Simeon Taylor, MD, PhD, professor of medicine and director of the Institutional Research Training Program in Diabetes & Obesity at the University of Maryland School of Medicine, Baltimore, told Medscape Medical News that the efficacy data were 'amazing,' and that the combination 'delivered unprecedented efficacy as judged by biomarkers, specifically the combination of loss of fat mass plus the increase in lean mass. These changes were accompanied by clinically meaningful improvements in blood pressure and glycemic indices. It will be critical to understand the impact on 'hard' clinical endpoints such as cardiovascular outcomes.' However, Taylor added that the trial raised some safety concerns, particularly an increase in LDL cholesterol that the investigators said was transient, but they didn't present data about what measures might have been used by the individual clinicians in the study to mitigate that rise. 'It will be important for the investigators to clarify how statin doses were managed. If the adverse effects of bimagrumab were transient, that could be a favorable scenario. If the LDL cholesterol returned toward baseline because statin doses were increased, that would have different implications,' he said. Obesity expert Amy E. Rothberg, MD, clinical professor of internal medicine and of nutritional sciences at the University of Michigan, Ann Arbor, agreed, and also cited other missing information, such as muscle quality. 'There were no biopsies done. They were doing DEXA. That tells us about distribution and volume, but it doesn't tell us anything about quality.' Rothberg also noted that the only objective functional measure was hand grip, while the rest were self-administered survey instruments. 'There are a lot of unknowns, but impressive data just the same.' Hard to Predict Safety Concerns Common adverse events with bimagrumab-containing groups included muscle spasms (ranging from 46.4% with 10 mg to 63.6% with the high-dose combination), diarrhea, and acne, while semaglutide was associated with the typical nausea, diarrhea, constipation, and fatigue. Similar events occurred in the four combination groups, in which 9% of those treated discontinued due to adverse events over 72 weeks. There were no deaths. The bimagrumab-containing groups showed early and transient increases in alanine aminotransferase and lipase, while semaglutide-containing groups had sustained increases in lipase. 'The biology of activin receptors is extremely complex. It is hard to predict all of the possible safety concerns. Phase 3 studies and pharmacovigilance will provide better understanding,' Taylor told Medscape Medical News . 'Some potential safety issues only become apparent when large numbers of people have taken the drug for long periods of time, he said, adding that 'obesity drugs are understandably required to have a very 'clean' safety profile.' The BELIEVE phase 2 study was essentially proof-of-concept, said Heymsfield. Semaglutide is a product of Lilly competitor Novo Nordisk. This unusual situation came about because the study was initiated in 2023 by Versanis Bio, which Lilly later acquired. Lilly is now conducting phase 2 trials of bimagrumab with its own GLP-1-based drug tirzepatide, this time co-formulated with bimagrumab in a subcutaneous injection. Heymsfield has a contract with Lilly for clinical trials (institutional support). He has received honoraria for serving on medical advisory boards of Tanita Corporation, Novo Nordisk, Lilly, Regeneron, Abbott, and Medifast. He is on the Data Safety Monitoring Committee for Novo Nordisk. Aronne receives consulting fees from/and serving on advisory boards for Altimmune, Atria, Eli Lilly, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Juvena Therapeutics, Kallyope, Novartis, Novo Nordisk, Pfizer, Prosciento, Senda Biosciences, Versanis, Veru Pharmaceuticals, and Zealand Pharmaceuticals; receives research funding from AstraZeneca, United Kingdom, Eli Lilly, Janssen Pharmaceuticals, Belgium, and Novo Nordisk, Denmark; having equity interests in ERX Pharmaceuticals, Intellihealth, Jamieson Wellness, Kallyope, Myos Corp, and Veru Pharmaceuticals; and serves on a board of directors for ERX Pharmaceuticals, Intellihealth, and Jamieson Wellness. Taylor has reported receiving payments from the National Institute of Diabetes and Digestive and Kidney Diseases for an inventor's share of a patent covering metreleptin as a treatment for generalized lipodystrophy. He was employed by Eli Lilly in 2000-2002 and Bristol Myers Squibb in 2002-2013.